MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022...
– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages through...
GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer Effects Observed Across Multiple Dose...
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trialsNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE...
Marc Malandro POAI Scientific Advisory BoardEAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the...
Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All Six Target Clinical Sites are...
Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13,...
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
In December 2022, the 15th patient was dosed with IMX-110IMX-110 clinical trial data expected to be released on a rolling...
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®)...
Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in...
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel...
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration...
HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of...
Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital...
CINCINNATI, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
Media Release Event to be held live in New Orleans, LouisianaMeeting to be webcast live and archived on www.genmab.com Copenhagen,...
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the...